We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Neurology

Journal Scan / Research · August 26, 2020

Viltolarsen Treatment in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping

JAMA Neurology

 

Additional Info

JAMA Neurology
Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial
JAMA Neurol 2020 Aug 01;77(8)982-991, PR Clemens, VK Rao, AM Connolly, AD Harper, JK Mah, EC Smith, CM McDonald, CM Zaidman, LP Morgenroth, H Osaki, Y Satou, T Yamashita, EP Hoffman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading